Objectives: To identify the genetic basis of resistance as well as to better understand the epidemiology of a recent surge in azithromycin-resistant Neisseria gonorrhoeae in New South Wales, Australia.
Introduction
Antimicrobial resistance amongst Neisseria gonorrhoeae is an ongoing global health challenge and this is highlighted by the fact that the gonococcus is now considered a 'high' priority organism by the WHO for research and development of new antibiotic treatments. 1 Ceftriaxone and azithromycin dual therapy is the first-line treatment for gonorrhoea in most settings. Azithromycin has only relatively recently been combined with ceftriaxone in this dual therapy gonorrhoea treatment as a means of protecting against further development of ceftriaxone resistance in N. gonorrhoeae. Over the last 7 years, there have been several reports of ceftriaxone-resistant strains from Japan, Europe and Australia [2] [3] [4] [5] [6] [7] that have raised concerns over potentially 'untreatable' N. gonorrhoeae. Fortunately, these ceftriaxone-resistant strains have only been sporadic and there have been no reports of sustained transmission of ceftriaxone-resistant gonococci. Hence, ceftriaxone remains an effective treatment for gonococcal infection. In contrast, the use of azithromycin for gonorrhoea treatment is in serious jeopardy. In recent years there has been some limited evidence to suggest that this dual therapy approach has led to a decline in the number of isolates exhibiting decreased susceptibility to ceftriaxone. 8, 9 However, over the same time period there have been significant increases in N. gonorrhoeae isolates exhibiting resistance to azithromycin, and azithromycin is now above the WHO 5% threshold in many regions. For example, the most recent Euro-GASP data showed 7.1% of isolates in Europe were resistant to azithromycin in 2015. 8 Of particular concern was our recent report demonstrating a sudden escalation in azithromycin-resistant N. gonorrhoeae in the Australian state of South Australia, whereby over a 3 month period beginning in late 2015 azithromycin resistance increased from approximately 5.0% to 30%. 10 This South Australian outbreak was attributed to a single gonococcal strain harbouring a 23S rRNA C2611T alteration and spreading amongst heterosexuals. It subsequently led to a change in treatment guidelines such that azithromycin monotherapy was no longer recommended for cases in which use of ceftriaxone was contraindicated. 10 In this study, we investigated a further outbreak of azithromycin-resistant N. gonorrhoeae in the Australian state of New South Wales where levels have increased from 3.6% in 2016 to 9.6% in the first half-year of 2017. [11] [12] [13] Of note was that this outbreak disproportionately affected men and so appeared to be primarily in networks of MSM. Additionally, we were intrigued by the fact that the majority of isolates (75%) exhibited MICs that were on the azithromycin breakpoint of 1.0 mg/L. This was different from the South Australian outbreak in which the majority of isolates were in the 2.0 to 8.0 mg/L range. These differences in MIC could potentially be explained by differences in the underlying resistance mechanism; N. gonorrhoeae azithromycin resistance is most commonly associated with the 23rRNA C2611T and A2059G mutations that confer 'low-level' (MICs typically in the range 1.0 to 16.0 mg/L) and 'high-level' (MICs typically 256 mg/L) resistance, respectively. However, we have also reported N. gonorrhoeae strains harbouring a variant 'meningococcal-type' mtrR-encoded efflux pump regulator that is associated with reduced susceptibility/low-level resistance to azithromycin, with MICs in the range of 0.12 to 1.0 mg/L.
14 Hence, to identify the genetic basis of the resistance as well as to better understand the local epidemiology, we applied a previously described iPLEX genotyping method 15 to isolates from the New South Wales outbreak.
Methods
A total of 124 N. gonorrhoeae isolates were included in the study. These comprised all available N. gonorrhoeae isolates from New South Wales in the period from January to July 2017 and exhibited azithromycin MICs 1.0 mg/L by Etest V R (bioMérieux, Australia). 16 The isolates were genotyped by a previously described high-throughput iPLEX method which characterizes single-nucleotide polymorphisms on gonococcal housekeeping genes to predict an MLST as well as detecting recognized resistance mutations on the gonococcal 23S rRNA, gyrA, mtrR, penA and ponA genes. 15 As originally described, the iPLEX method detects both the 23rRNA C2611T and A2059G mutations associated with azithromycin resistance; however, for this study we modified the protocol to also enable detection of the meningococcaltype mtrR variant. In brief, two new oligonucleotides (ACGTTGGATGATAATGG CGGTTTCGTTCC and ACGTTGGATGATACATACACAATTGCACGG) were added to the initial PCR amplification as well as two new oligonucleotides (GTCGGCGCGGTTTGACG and CGCGGGTCGGTTTGACG) to the extension reaction. All iPLEX testing was conducted at the Australian Genome Research Facility (Brisbane, Queensland). The study was approved by the Human Research Ethics Committees of the South Eastern Sydney Local Health District (reference number 14/057) and The University of Queensland (reference number 201500111699).
Results
Of the total 124 isolates included in the study, 118 isolates from 118 patients (107 males, 1 transsexual and 10 females) were successfully genotyped by the iPLEX method. The genotyping results for all 118 isolates and associated data are summarized in Table 1 and further detailed in Table S1 (available as Supplementary data at JAC Online). The remaining six isolates that failed to genotype were excluded from further analysis. In brief, the genotyping revealed 10 different genotypes, henceforth called AZI-G1 to AZI-G10 (Table 1) and that the azithromycin resistance was attributable to one of two different mechanisms; the 23S rRNA C2611T mutation (genotypes AZI-G1 to AZI-G7) accounted for 28 isolates (24%; 28/118), whereas the majority of resistance [90 isolates; 76% (90/118)] was associated with the meningococcal-type mtrR variant (genotypes AZI-G8 to AZI-G10). The most common genotype was AZI-G10 (88 isolates; 87 males and 1 transsexual) followed by AZI-G4 (13 isolates; 7 males and 6 females) and AZI-G7 (8 isolates; 7 males and 1 female) and all three genotypes were observed throughout most months of the study period (see 'Month of collection'; Table 1 ). The remaining seven genotypes comprised only one or two isolates each (nine isolates in total; six males, three females). Based on the relative numbers of males and females, the AZI-G10 genotype was considered to be primarily circulating amongst MSM and the AZI-G4 amongst heterosexuals. The patient numbers for the remaining genotypes were considered too low to determine the sexual network.
Categorization of susceptibility to antibiotics listed in Table 1 is based on the Australian Gonococcal Surveillance Programme (AGSP) interpretative criteria. 16 The azithromycin MICs associated with each alteration were significantly (P , 0.001) different; only 3 (11%; 3/28) isolates with the C2611T mutation had an MIC of 1.0 mg/L, whereas the remainder (89%; 25/28) had MICs in the 2.0 to 8.0 mg/L range. In contrast, the majority of isolates with the meningococcal-type mtrR variant (96%; 86/90) had an MIC of 1.0 mg/L, whereas the remaining 4 (4%; 4/90) had an MIC of 2.0 mg/L. Of further interest was a single isolate of genotype AZI-G5 (Table 1) harbouring a 23S C2611T mutation as well as a mosaic penA sequence, the latter being a key gonococcal cephalosporin resistance mechanism associated with resistance to cefixime and reduced susceptibility to ceftriaxone. This AZI-G5 isolate was subjected to additional DNA sequencing and was shown to be of MLST 1901, a novel N. gonorrhoeae multi-antigen sequence type (NG-MAST, yet to be assigned; novel porB allele and tbpB 110 allele) 17 and a novel N. gonorrhoeae Sequence Typing for Antimicrobial Resistance (NG-STAR) 18 type, 758; the latter NG-STAR typing confirmed the presence of a type XXXIV mosaic penA sequence.
Discussion
The results of the iPLEX genotyping show that the azithromycin resistance recently observed in New South Wales is primarily attributable to ongoing transmission of three azithromycinresistant N. gonorrhoeae strains, and is consistent with reports of similar strains and clusters elsewhere. [19] [20] [21] Moreover, the data indicate that in Australia we now have outbreaks of azithromycinresistant gonococci amongst networks of MSM and heterosexuals in at least two states, and raise questions over the long-term Azithromycin-resistant Neisseria gonorrhoeae JAC Table 1 .
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viability of azithromycin for gonorrhoea treatment in our country. One potential positive finding that can be taken from our data is that the majority of azithromycin resistance (76%) in New South Wales was attributable to a weaker type of resistance mechanism in the form of the meningococcal-type mtrR variant. The lower azithromycin MICs of these strains (compared with the 23S rRNA alterations) may render these less likely to result in treatment failure, particularly when treated with empirical ceftriaxone and azithromycin dual therapy. Further clinical studies are needed to assess this. However, it should be noted that the ceftriaxone MICs for these strains at 0.008 mg/L were well below the ceftriaxone resistance breakpoint of .0.125 mg/L defined by EUCAST 22 as well as the decreased susceptibility breakpoint of 0.06 mg/L used by the AGSP. 11, 16 Of concern was the identification of the AZI-G5 isolate harbouring both the C2611T and mosaic penA alterations. The previously described ceftriaxone-resistant N. gonorrhoeae strains have all harboured a mosaic penA sequence, with one more additional mutation in the mosaic penA leading to the ceftriaxone-resistant phenotype. Hence, this AZI-G5 isolate represents a gonococcal strain that is arguably only one mutation away from exhibiting resistance to both ceftriaxone and azithromycin. Gonococcal strains harbouring both the C2611T and mosaic penA mechanisms are presumably rare, and to our knowledge there has only been one other report of such a strain involving four isolates in the Netherlands. 20 Intriguingly, the four Dutch isolates were of NG-MAST (1407) having 98.6% sequence similarity (868/880 bases matching; 478/490 bases for porB and 390/390 matching for tbpB) to the NG-MAST type of our strain. Thus, the results suggest this may be a gonococcal clone that is circulating internationally and perhaps 'flying under the radar' of routine surveillance. In this context, it is of note that if not for the iPLEX genotyping data the significance of this particular AZI-G5 isolate would not have been realized.
A limitation of this study was that we did not have access to information regarding patient sexuality or sexual contacts, and so assignment to networks of either MSM or heterosexuals was based only on the relative numbers of males and females for each genotype.
Taken as a whole, these data provide further evidence that we are fast losing azithromycin as an adjunctive treatment option for gonococcal infection, and again highlights the urgent need to explore alternative therapies for gonorrhoea. The results also further demonstrate the benefits of using molecular methods, including our high-throughput iPLEX method, to enhance phenotypic-based N. gonorrhoeae resistance surveillance and to identify underlying trends and threats.
